<DOC>
	<DOCNO>NCT01776996</DOCNO>
	<brief_summary>This open-label protocol design provide continued access maraviroc subject complete previous study maraviroc continue receive clinical benefit .</brief_summary>
	<brief_title>An Expanded Access Protocol Subjects Who Have Completed Clinical Studies Involving Maraviroc</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Subject participate clinical trial evaluate maraviroc continue derive clinical benefit maraviroc treatment . Subject must agree use acceptable method contraception duration study outline end inclusion criterion . Subject agree specify study procedure . Subject investigational site staff member employee Sponsor directly involve conduct trial . Other severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation , judgment investigator , would make subject inappropriate entry study . Contraindications use maraviroc described Investigator Brochure . Past document dual/mixed CXC chemokine receptor type 4 HIV tropism .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Expanded access , HIV , maraviroc</keyword>
</DOC>